D
Edgewise Therapeutics, Inc.
EWTX
$12.05
-$1.53-11.27%
D
Sell
12/27/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 12/27/2023 due to an increase in the volatility index and total return index.
E
Sell
12/5/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 12/5/2023 due to a decline in the volatility index.
D
Sell
11/20/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 11/20/2023 due to an increase in the volatility index and total return index.
E
Sell
10/3/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 10/3/2023 due to a decline in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 10/3/2023 due to a decline in the volatility index and total return index.
D
Sell
9/18/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 9/18/2023 due to an increase in the volatility index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 9/18/2023 due to an increase in the volatility index and valuation index.
E
Sell
8/28/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 8/28/2023 due to a decline in the total return index, volatility index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 8/28/2023 due to a decline in the total return index, volatility index and valuation index.
D
Sell
8/11/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 8/11/2023 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 11.36% from -$22.83M to -$20.23M, earnings per share increased from -$0.361 to -$0.34, and EBIT increased 1.42% from -$25.7M to -$25.34M.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 8/11/2023 due to an increase in the growth index, volatility index and valuation index. Operating cash flow increased 11.36% from -$22.83M to -$20.23M, earnings per share increased from -$0.361 to -$0.34, and EBIT increased 1.42% from -$25.7M to -$25.34M.
E
Sell
7/31/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
D
Sell
7/14/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 7/14/2023 due to an increase in the volatility index, total return index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 7/14/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
6/23/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 6/23/2023 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 6/23/2023 due to a decline in the volatility index.
D
Sell
6/7/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 6/7/2023 due to an increase in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 6/7/2023 due to an increase in the volatility index and total return index.
E
Sell
5/18/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 5/18/2023 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 93.11% from -$11.82M to -$22.83M, earnings per share declined from -$0.307 to -$0.361, and EBIT declined 16.42% from -$22.08M to -$25.7M.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 5/18/2023 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 93.11% from -$11.82M to -$22.83M, earnings per share declined from -$0.307 to -$0.361, and EBIT declined 16.42% from -$22.08M to -$25.7M.
D
Sell
5/9/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 5/9/2023 due to an increase in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 5/9/2023 due to an increase in the volatility index.
E
Sell
4/19/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 4/19/2023 due to a decline in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 4/19/2023 due to a decline in the volatility index and total return index.
D
Sell
4/3/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
2/24/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 2/24/2023 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.3375 to -$0.307, and operating cash flow increased 1.48% from -$12M to -$11.82M.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 2/24/2023 due to an increase in the growth index and volatility index. Earnings per share increased from -$0.3375 to -$0.307, and operating cash flow increased 1.48% from -$12M to -$11.82M.
D
Sell
2/21/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 2/21/2023 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 2/21/2023 due to a decline in the volatility index.
D
Sell
2/3/2023Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 2/3/2023 due to an increase in the volatility index and total return index.
D
Sell
1/13/2023Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 1/13/2023 due to a decline in the volatility index, total return index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 1/13/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
12/28/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 12/28/2022 due to an increase in the volatility index, total return index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 12/28/2022 due to an increase in the volatility index, total return index and valuation index.
D
Sell
12/7/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 12/7/2022 due to a decline in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 12/7/2022 due to a decline in the volatility index and total return index.
D
Sell
11/21/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 11/21/2022 due to an increase in the solvency index, volatility index and valuation index. The quick ratio increased from 26.95 to 27.42.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 11/21/2022 due to an increase in the solvency index, volatility index and valuation index. The quick ratio increased from 26.95 to 27.42.
D
Sell
10/19/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index.
D
Sell
9/23/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 9/23/2022 due to an increase in the volatility index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from D- on 9/23/2022 due to an increase in the volatility index and total return index.
D
Sell
9/8/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 9/8/2022 due to an increase in the volatility index, total return index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 9/8/2022 due to an increase in the volatility index, total return index and valuation index.
E
Sell
8/24/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 8/24/2022 due to a decline in the volatility index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 8/24/2022 due to a decline in the volatility index and valuation index.
D
Sell
8/8/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 8/8/2022 due to an increase in the solvency index, volatility index and growth index. The quick ratio increased from 26.57 to 26.95.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 8/8/2022 due to an increase in the solvency index, volatility index and growth index. The quick ratio increased from 26.57 to 26.95.
E
Sell
7/27/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 7/27/2022 due to a decline in the volatility index and valuation index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 7/27/2022 due to a decline in the volatility index and valuation index.
D
Sell
7/7/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 7/7/2022 due to an increase in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 7/7/2022 due to an increase in the volatility index.
E
Sell
6/21/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 6/21/2022 due to a decline in the volatility index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 6/21/2022 due to a decline in the volatility index.
D
Sell
5/31/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 33.47% from -$9.42M to -$12.57M, EBIT declined 15.63% from -$12.82M to -$14.83M, and earnings per share declined from -$0.2572 to -$0.2959.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 5/13/2022 due to a decline in the growth index, volatility index and solvency index. Operating cash flow declined 33.47% from -$9.42M to -$12.57M, EBIT declined 15.63% from -$12.82M to -$14.83M, and earnings per share declined from -$0.2572 to -$0.2959.
D
Sell
5/5/2022Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 05/05/2022.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D- from E+ on 05/05/2022.
E
Sell
4/20/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index.
D
Sell
3/25/2022Downgrade
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 3/25/2022 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 33.18 to 26.69, and total capital declined 3.86% from $285.4M to $274.38M.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to D- from D on 3/25/2022 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 33.18 to 26.69, and total capital declined 3.86% from $285.4M to $274.38M.
D
Sell
11/9/2021Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from E on 11/09/2021.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to D from E on 11/09/2021.
E
Sell
9/1/2021Upgraded
Edgewise Therapeutics, Inc. (EWTX) was upgraded to E from E- on 9/1/2021 due to an increase in the valuation index.
Edgewise Therapeutics, Inc. (EWTX) was upgraded to E from E- on 9/1/2021 due to an increase in the valuation index.
E
Sell
8/10/2021None
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E- from U on 08/10/2021.
Edgewise Therapeutics, Inc. (EWTX) was downgraded to E- from U on 08/10/2021.
NASDAQ
04/04/2025 12:56PM Eastern
Quotes delayed
